With the rapid advancement in the field of immunology and rheumatology, ACPAs may serve not only as a clinical marker but also as a therapeutic target for ACPA-positive RA patients with an erosive phenotype one day. This evidence concerns the gene PRTN3 and rheumatoid arthritis.